

Media Release

Zug, 2 July 2025

HBM Healthcare Investments launches new share buyback programme

At the Annual General Meeting of HBM Healthcare Investments AG on 23 June 2025, shareholders approved a new share buyback programme for a maximum of 674,000 shares (corresponding to 10% of the shares registered in the commercial register) for the purpose of cancellation through a capital reduction.

The buyback programme will be carried out via a dedicated trading line on the SIX Swiss Exchange, with Zürcher Kantonalbank being entrusted with this task. The programme is scheduled to commence on Friday, 4 July 2025 and is expected to conclude on 3 July 2028 at the latest.

Further information on the new 2025 buyback programme is available on the company website at <u>https://www.hbmhealthcare.com/en/investors/information</u>.

Contact us

For further information, please contact Dr Andreas Wicki on +41 41 710 75 77, or at <u>andreas.wicki@hbmhealthcare.com</u>

About HBM Healthcare Investments

HBM Healthcare Investments invests in the healthcare sector. The Company holds and manages an international portfolio of promising companies in the human medicine, biotechnology, medical technology and diagnostics sectors and related areas. Many of these companies have their lead products already available on the market or at an advanced stage of development. The portfolio companies are closely tracked and actively guided in their strategic direction. This is what makes HBM Healthcare Investments an interesting alternative to investments in big pharma and biotechnology companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

HBM Healthcare Investments

Disclaimer

The publication is for information purposes only and does not constitute an offer to sell or a solicitation to buy or subscribe for securities. This news release does not constitute a prospectus within the meaning of Art. 35ff FinSA, or securities prospectus in the sense of the German securities prospectus law. This news release and the information contained therein is not intended for distribution to the United States of America (USA) or within the USA and may not be distributed or forwarded to U.S. persons (including legal persons) or to publications with a general distribution in the USA. This news release is not an offer or solicitation to buy securities in the United States. HBM Healthcare Investments Ltd's securities were not issued in accordance with the U.S. securities laws, and may not be sold, offered for sale, or delivered in the U.S. or to U.S. individuals without prior registration or without a registration exemption. Some information quoted was obtained from external sources HBM considers to be reliable. HBM cannot guarantee the adequacy, accuracy, timeliness or completeness of or be held responsible or liable for errors of fact regarding such data and information obtained from third parties, and this data may change with market conditions.